(VIANEWS) – Shares of PHARMING GROUP (AEX-Index: PHARM.AS) fell by a staggering 13.16% to €1.02 at 11:08 EST on Thursday, after five sequential sessions in a row of gains. AEX-Index is jumping 0.84% to €754.57, after two consecutive sessions in a row of losses. This seems, up until now, a somewhat positive trend trading session today.
About PHARMING GROUP
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's commercialized product is RUCONEST, a plasma-free rhC1INH protein replacement therapy for the treatment acute hereditary angioedema (HAE) attacks. It also engages in the development of leniolisib for the treatment of activated phosphoinositide 3-kinase delta syndrome; OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE; and alpha-glucosidase therapy for the treatment of Pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. is headquartered in Leiden, the Netherlands.
Earnings Per Share
As for profitability, PHARMING GROUP has a trailing twelve months EPS of €0.02.
PE Ratio
PHARMING GROUP has a trailing twelve months price to earnings ratio of 51.15. Meaning, the purchaser of the share is investing €51.15 for every euro of annual earnings.
Volume
Today’s last reported volume for PHARMING GROUP is 19241711 which is 79.07% above its average volume of 10744900.
More news about PHARMING GROUP (PHARM.AS).
